John Blankenship
Company: Novartis
Job title: Senior Investigator & Group Leader - Antibody Discovery
Seminars:
Panel Discussion: Examining Trends & Future Opportunities in this Rapidly Evolving Space – What Does the Future of the BioSpecific Look Like? 3:30 pm
• What leads to a program being pulled from the clinic? • What are early warning signs that have proved good predictors of failures in scale up? • At which stage are failures typically occurring and why? • Investigating the relative roles of factors such as manufacturability, toxicity and selectivityRead more
day: Day Two
Panel Discussion: Solving the Specificity Problem to Pioneer Bispecifics in Solid Tumor Indications 9:25 am
Understanding the specific requirements for therapeutics targeting solid tumor indications and contrasting them with hematological malignancies Mitigating against on-target off-tumor toxicities by establishing more nuanced targeting approaches Lessons learned from solid tumor targeting with a range of therapeutics – how can these strategies be applied to the bispecific space?Read more
day: Day One